Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2021

14.04.2021 | Sarcoma

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group

verfasst von: Carol J. Swallow, MD, PhD, Dirk C. Strauss, MD, Sylvie Bonvalot, MD, PhD, Piotr Rutkowski, MD, PhD, Anant Desai, MD, Rebecca A. Gladdy, MD, PhD, Ricardo Gonzalez, MD, David E. Gyorki, MBBS, MD, Mark Fairweather, MD, Winan J. van Houdt, MD, PhD, Eberhard Stoeckle, MD, Jae Berm Park, MD, PhD, Markus Albertsmeier, PD, Dr.med., Carolyn Nessim, MD, MSc, Kenneth Cardona, MD, Marco Fiore, MD, Andrew Hayes, MA, PhD, Dimitri Tzanis, MD, PhD, Jacek Skoczylas, MD, Samuel J. Ford, MB, ChB, PhD, Deanna Ng, MBBS, John E. Mullinax, MD, Hayden Snow, MBBS, Rick L. Haas, MD, PhD, Dario Callegaro, MD, Myles J. Smith, MB, BCh, BAO, PhD, Toufik Bouhadiba, MD, Silvia Stacchiotti, MD, Robin L. Jones, MBBS, MD(Res), Thomas DeLaney, MD, Christina L. Roland, MD, Chandrajit P. Raut, MD MSc, Alessandro Gronchi, MD, on behalf of the Transatlantic Australasian RPS Working Group (TARPSWG)

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document.

Methods

The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation.

Results

Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies.

Conclusions

Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.
Literatur
1.
Zurück zum Zitat Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–6.PubMedCrossRef Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–6.PubMedCrossRef
2.
Zurück zum Zitat Ferrari A, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943–9.PubMedPubMedCentralCrossRef Ferrari A, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57(6):943–9.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Cormier JN, Gronchi A, Pollock RE. Soft tissue sarcomas. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, et al. (eds). Schwartz’s principles of surgery 10th edition. New York: McGraw-Hill; 2014. Cormier JN, Gronchi A, Pollock RE. Soft tissue sarcomas. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, et al. (eds). Schwartz’s principles of surgery 10th edition. New York: McGraw-Hill; 2014.
4.
Zurück zum Zitat Dei Tos AP, Marino-Enriquez A, Pedeutour F. Soft Tissue Tumours. In: WHO Classification of Tumours Editorial Board (eds). WHO Classification of Tumours of Soft Tissue and Bone. Fifth Edition, Volume 3. Lyon: IARC Publications; 2020. Dei Tos AP, Marino-Enriquez A, Pedeutour F. Soft Tissue Tumours. In: WHO Classification of Tumours Editorial Board (eds). WHO Classification of Tumours of Soft Tissue and Bone. Fifth Edition, Volume 3. Lyon: IARC Publications; 2020.
5.
Zurück zum Zitat Lewis JJ, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65.PubMedPubMedCentralCrossRef Lewis JJ, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Stoeckle E, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92(2):359–68.PubMedCrossRef Stoeckle E, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92(2):359–68.PubMedCrossRef
7.
Zurück zum Zitat Gronchi A, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100(11):2448–55.PubMedCrossRef Gronchi A, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100(11):2448–55.PubMedCrossRef
8.
Zurück zum Zitat Hassan I, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004;239(2):244–50.PubMedPubMedCentralCrossRef Hassan I, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004;239(2):244–50.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat van Dalen T, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2007;33(2):234–8.PubMedCrossRef van Dalen T, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2007;33(2):234–8.PubMedCrossRef
10.
Zurück zum Zitat Lehnert T, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol. 2009;35(9):986–93.PubMedCrossRef Lehnert T, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol. 2009;35(9):986–93.PubMedCrossRef
11.
Zurück zum Zitat Anaya DA, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249(1):137–42.PubMedCrossRef Anaya DA, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision-making. Ann Surg. 2009;249(1):137–42.PubMedCrossRef
12.
Zurück zum Zitat Strauss DC, et al. Surgical management of primary retroperitoneal sarcoma. Br J Surg. 2010;97(5):698–706.PubMedCrossRef Strauss DC, et al. Surgical management of primary retroperitoneal sarcoma. Br J Surg. 2010;97(5):698–706.PubMedCrossRef
13.
Zurück zum Zitat Bonvalot S, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–7.PubMedCrossRef Bonvalot S, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27(1):31–7.PubMedCrossRef
14.
Zurück zum Zitat Gronchi A, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27(1):24–30.PubMedCrossRef Gronchi A, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27(1):24–30.PubMedCrossRef
15.
Zurück zum Zitat Bonvalot S, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17(6):1507–14.PubMedCrossRef Bonvalot S, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17(6):1507–14.PubMedCrossRef
16.
Zurück zum Zitat Gronchi A, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23(4):1067–73.PubMedCrossRef Gronchi A, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012;23(4):1067–73.PubMedCrossRef
17.
Zurück zum Zitat Singer S, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–70.PubMedPubMedCentralCrossRef Singer S, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–70.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Dalal KM, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244(3):381–91.PubMedPubMedCentralCrossRef Dalal KM, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244(3):381–91.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Almond LM, et al. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(5):571–9.PubMedCrossRef Almond LM, et al. Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(5):571–9.PubMedCrossRef
21.
Zurück zum Zitat Bonvalo S, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77.CrossRef Bonvalo S, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77.CrossRef
22.
Zurück zum Zitat Bonvalot S, et al. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. Ann Surg Oncol. 2019;26(7):2286–93.PubMedCrossRef Bonvalot S, et al. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. Ann Surg Oncol. 2019;26(7):2286–93.PubMedCrossRef
24.
Zurück zum Zitat Raut CP, Bonvalot S, Gronchi A. A call to action: Why sarcoma surgery needs to be centalized. Cancer. 2018;124(23):4452–4.PubMedCrossRef Raut CP, Bonvalot S, Gronchi A. A call to action: Why sarcoma surgery needs to be centalized. Cancer. 2018;124(23):4452–4.PubMedCrossRef
25.
Zurück zum Zitat Gronchi A, Pollock R. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011;18(8):2107–10.PubMedCrossRef Gronchi A, Pollock R. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011;18(8):2107–10.PubMedCrossRef
26.
Zurück zum Zitat van Houdt WJ, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. Curr Opin Oncol. 2019;31(4):310-316. van Houdt WJ, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. Curr Opin Oncol. 2019;31(4):310-316.
27.
Zurück zum Zitat Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015;22(1):256-63. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015;22(1):256-63.
28.
Zurück zum Zitat Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2016;23(11):3531-3540. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2016;23(11):3531-3540.
29.
Zurück zum Zitat Management of metastatic retroperitoneal sarcoma. a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29(4):857–71.CrossRef Management of metastatic retroperitoneal sarcoma. a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29(4):857–71.CrossRef
30.
31.
Zurück zum Zitat Heudel PE, et al. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhone-Alpes region. Int J Clin Oncol. 2014;19(4):744–52.PubMed Heudel PE, et al. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhone-Alpes region. Int J Clin Oncol. 2014;19(4):744–52.PubMed
32.
Zurück zum Zitat Keung EZ, et al. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer. 2018;124(23):4495–503.PubMedCrossRef Keung EZ, et al. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer. 2018;124(23):4495–503.PubMedCrossRef
33.
Zurück zum Zitat Toulmonde M, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25(3):735–42.PubMedPubMedCentralCrossRef Toulmonde M, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25(3):735–42.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Villano AM, et al. Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. J Am Coll Surg. 2020;230(1):151-160.e2.PubMedCrossRef Villano AM, et al. Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. J Am Coll Surg. 2020;230(1):151-160.e2.PubMedCrossRef
35.
36.
Zurück zum Zitat Andritsch E, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017; 110:94-105. Andritsch E, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017; 110:94-105.
37.
Zurück zum Zitat Messiou C, Morosi C. Imaging in retroperitoneal soft tissue sarcoma. J Surg Oncol. 2018;117(1):25–32.PubMedCrossRef Messiou C, Morosi C. Imaging in retroperitoneal soft tissue sarcoma. J Surg Oncol. 2018;117(1):25–32.PubMedCrossRef
38.
Zurück zum Zitat Messiou C, et al. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol. 2017;43(7):1191–8.PubMedCrossRef Messiou C, et al. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol. 2017;43(7):1191–8.PubMedCrossRef
39.
Zurück zum Zitat Kim DB, et al. Effect of nephrectomy for retroperitoneal sarcoma on post-operative renal function. J Surg Oncol. 2018;117(3):425–9.PubMedCrossRef Kim DB, et al. Effect of nephrectomy for retroperitoneal sarcoma on post-operative renal function. J Surg Oncol. 2018;117(3):425–9.PubMedCrossRef
40.
Zurück zum Zitat Fendler WP, et al. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. Eur Radiol. 2015;25(8):2214–21.PubMedCrossRef Fendler WP, et al. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. Eur Radiol. 2015;25(8):2214–21.PubMedCrossRef
41.
Zurück zum Zitat von Mehren M, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(5):536-563. von Mehren M, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(5):536-563.
42.
Zurück zum Zitat Casali PG, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29 Suppl 4:iv51–iv67. Casali PG, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29 Suppl 4:iv51–iv67.
43.
Zurück zum Zitat Miah AB, et al. Optimal management of primary retroperitoneal sarcoma: an update. Expert Rev Anticancer Ther. 2014;14(5):565–79.PubMedCrossRef Miah AB, et al. Optimal management of primary retroperitoneal sarcoma: an update. Expert Rev Anticancer Ther. 2014;14(5):565–79.PubMedCrossRef
44.
Zurück zum Zitat Wilkinson MJ, et al. Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival. Ann Surg Oncol. 2015;22(3):853–8.PubMedCrossRef Wilkinson MJ, et al. Percutaneous core needle biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival. Ann Surg Oncol. 2015;22(3):853–8.PubMedCrossRef
45.
Zurück zum Zitat Thway K, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36(3):462–9.PubMedCrossRef Thway K, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012;36(3):462–9.PubMedCrossRef
46.
Zurück zum Zitat Lee ATJ, et al. Clinical and Molecular Spectrum of Liposarcoma. J Clin Oncol. 2018;36(2):151–9.PubMedCrossRef Lee ATJ, et al. Clinical and Molecular Spectrum of Liposarcoma. J Clin Oncol. 2018;36(2):151–9.PubMedCrossRef
47.
Zurück zum Zitat Sirvent N, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–89.PubMedCrossRef Sirvent N, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31(10):1476–89.PubMedCrossRef
48.
Zurück zum Zitat Demicco EG, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015;143(5):672–82.PubMedCrossRef Demicco EG, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol. 2015;143(5):672–82.PubMedCrossRef
49.
Zurück zum Zitat Trojani M, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42.PubMedCrossRef Trojani M, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37–42.PubMedCrossRef
50.
Zurück zum Zitat Lahat G, et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer. 2009;115(5):1081–90.PubMedCrossRef Lahat G, et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer. 2009;115(5):1081–90.PubMedCrossRef
51.
Zurück zum Zitat Berger-Richardson D, et al. Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers. Ann Surg Oncol. 2019;26(13):4692–8.PubMedCrossRef Berger-Richardson D, et al. Early and Late Complications of Percutaneous Core Needle Biopsy of Retroperitoneal Tumors at Two Tertiary Sarcoma Centers. Ann Surg Oncol. 2019;26(13):4692–8.PubMedCrossRef
52.
Zurück zum Zitat Van Houdt WJ, et al. Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol. 2017;43(9):1740–5.PubMedCrossRef Van Houdt WJ, et al. Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol. 2017;43(9):1740–5.PubMedCrossRef
53.
Zurück zum Zitat Gronchi A, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649–55.PubMedCrossRef Gronchi A, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649–55.PubMedCrossRef
54.
Zurück zum Zitat Martin Broto J, Le Cesne A, Reichardt P. The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncol. 2017;13(1s):23–31.PubMedCrossRef Martin Broto J, Le Cesne A, Reichardt P. The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncol. 2017;13(1s):23–31.PubMedCrossRef
55.
Zurück zum Zitat Kirov KM, et al. Role of nutritional status in the early postoperative prognosis of patients operated for retroperitoneal liposarcoma (RLS): A single center experience. Eur J Surg Oncol. 2019;45(2):261–7.PubMedCrossRef Kirov KM, et al. Role of nutritional status in the early postoperative prognosis of patients operated for retroperitoneal liposarcoma (RLS): A single center experience. Eur J Surg Oncol. 2019;45(2):261–7.PubMedCrossRef
56.
Zurück zum Zitat Previtali P, et al. Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. Ann Surg Oncol. 2019;17(10):019–08121. Previtali P, et al. Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. Ann Surg Oncol. 2019;17(10):019–08121.
57.
Zurück zum Zitat Bonvalot S, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012;19(9):2981–91.PubMedCrossRef Bonvalot S, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012;19(9):2981–91.PubMedCrossRef
58.
Zurück zum Zitat Gronchi A, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002–9.PubMedCrossRef Gronchi A, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002–9.PubMedCrossRef
59.
Zurück zum Zitat Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev Anticancer Ther. 2019;19(7):613–31.PubMedCrossRef Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. Expert Rev Anticancer Ther. 2019;19(7):613–31.PubMedCrossRef
60.
Zurück zum Zitat Fairweather M, et al. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018;117(1):33–41.PubMedCrossRef Fairweather M, et al. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018;117(1):33–41.PubMedCrossRef
61.
Zurück zum Zitat Tseng WW, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(6):810–5.PubMedCrossRef Tseng WW, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. Eur J Surg Oncol. 2018;44(6):810–5.PubMedCrossRef
62.
Zurück zum Zitat Ng D, et al. Why were non-metastatic primary Retroperitoneal Sarcomas not resected? Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID 3042575. Ng D, et al. Why were non-metastatic primary Retroperitoneal Sarcomas not resected? Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID 3042575.
63.
Zurück zum Zitat Andraz P, et al. Inoperable Primary Retroperitoneal Sarcomas: clinical characteristics and reasons against resection at a single referral institution. Ann Surg Oncol. 2020. Submitted. Andraz P, et al. Inoperable Primary Retroperitoneal Sarcomas: clinical characteristics and reasons against resection at a single referral institution. Ann Surg Oncol. 2020. Submitted.
64.
Zurück zum Zitat Tseng WW, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014;21(7):2136–43.PubMedCrossRef Tseng WW, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014;21(7):2136–43.PubMedCrossRef
66.
Zurück zum Zitat Pisters PW, O’Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14(4):400–5.PubMedCrossRef Pisters PW, O’Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14(4):400–5.PubMedCrossRef
67.
Zurück zum Zitat Gilbeau L, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65(3):137–43.PubMedCrossRef Gilbeau L, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65(3):137–43.PubMedCrossRef
68.
Zurück zum Zitat Pawlik TM, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):508–17.PubMedCrossRef Pawlik TM, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):508–17.PubMedCrossRef
69.
Zurück zum Zitat Feng M, et al. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007;69(1):103–10.PubMedCrossRef Feng M, et al. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007;69(1):103–10.PubMedCrossRef
70.
Zurück zum Zitat Ballo MT, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67(1):158–63.PubMedCrossRef Ballo MT, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67(1):158–63.PubMedCrossRef
71.
Zurück zum Zitat Paryani NN, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012;82(3):1128–34.PubMedCrossRef Paryani NN, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012;82(3):1128–34.PubMedCrossRef
72.
Zurück zum Zitat Smith MJ, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014;110(1):165–71.PubMedCrossRef Smith MJ, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014;110(1):165–71.PubMedCrossRef
73.
Zurück zum Zitat Pisters PW, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21(16):3092–7.PubMedCrossRef Pisters PW, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21(16):3092–7.PubMedCrossRef
74.
Zurück zum Zitat Gronchi A, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50(4):784–92.PubMedCrossRef Gronchi A, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50(4):784–92.PubMedCrossRef
75.
Zurück zum Zitat Angele MK, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260(5):749–54.PubMedCrossRef Angele MK, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260(5):749–54.PubMedCrossRef
76.
Zurück zum Zitat Issels RD, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483–92.PubMedPubMedCentralCrossRef Issels RD, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483–92.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Radaelli S, et al. Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 2014;14(6):689–704.PubMedCrossRef Radaelli S, et al. Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 2014;14(6):689–704.PubMedCrossRef
78.
Zurück zum Zitat Alektiar KM, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63.PubMedCrossRef Alektiar KM, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63.PubMedCrossRef
79.
Zurück zum Zitat Gieschen HL, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):127–31.PubMedCrossRef Gieschen HL, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):127–31.PubMedCrossRef
80.
Zurück zum Zitat Yoon SS, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17(6):1515–29.PubMedPubMedCentralCrossRef Yoon SS, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17(6):1515–29.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat McBride SM, et al. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013;20(7):2140–7.PubMedCrossRef McBride SM, et al. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013;20(7):2140–7.PubMedCrossRef
82.
Zurück zum Zitat Roeder F, et al. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma. BMC Cancer. 2012;12:287.PubMedPubMedCentralCrossRef Roeder F, et al. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma. BMC Cancer. 2012;12:287.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat DeLaney TF, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017;2(1):85–93.PubMedPubMedCentralCrossRef DeLaney TF, et al. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017;2(1):85–93.PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Le Pechoux C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24(3):832–7.PubMedCrossRef Le Pechoux C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24(3):832–7.PubMedCrossRef
85.
Zurück zum Zitat Haas RL, et al. Radiation therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018;117(1):93–8.PubMedCrossRef Haas RL, et al. Radiation therapy in retroperitoneal sarcoma management. J Surg Oncol. 2018;117(1):93–8.PubMedCrossRef
86.
Zurück zum Zitat Fairweather M, et al. Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol. 2015;22(5):1455–63.PubMedCrossRef Fairweather M, et al. Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol. 2015;22(5):1455–63.PubMedCrossRef
87.
Zurück zum Zitat Dziewirski W, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol. 2006;13(2):245–52.PubMedCrossRef Dziewirski W, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol. 2006;13(2):245–52.PubMedCrossRef
88.
Zurück zum Zitat Raut C, et al. Why Primary Retroperitoneal Sarcoma (PRPS) Patients Undergoing Treatment At STRASS Institutions Did Not Enroll In STRASS: The STREXIT Study From EORTC STBSG And TARPSWG. Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID: 3042602. Raut C, et al. Why Primary Retroperitoneal Sarcoma (PRPS) Patients Undergoing Treatment At STRASS Institutions Did Not Enroll In STRASS: The STREXIT Study From EORTC STBSG And TARPSWG. Connective Tissue Oncology Society Meeting Final Program 2018. Abstract ID: 3042602.
89.
Zurück zum Zitat Pervaiz N, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef Pervaiz N, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef
90.
Zurück zum Zitat Woll PJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.PubMedCrossRef Woll PJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.PubMedCrossRef
91.
Zurück zum Zitat Gronchi A, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22.PubMedCrossRef Gronchi A, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22.PubMedCrossRef
92.
Zurück zum Zitat Canter RJ, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191–7.PubMedPubMedCentralCrossRef Canter RJ, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191–7.PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Haas RL, et al. Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. Int J Radiat Oncol Biol Phys. 2018;101(5):1226–33.PubMedCrossRef Haas RL, et al. Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. Int J Radiat Oncol Biol Phys. 2018;101(5):1226–33.PubMedCrossRef
94.
95.
Zurück zum Zitat Yahya Zaidi M, Cardona K. Post-operative surveillance in soft tissue sarcoma: using tumor-specific recurrence patterns to direct approach. Chin Clin Oncol. 2018;7(4):03. Yahya Zaidi M, Cardona K. Post-operative surveillance in soft tissue sarcoma: using tumor-specific recurrence patterns to direct approach. Chin Clin Oncol. 2018;7(4):03.
96.
Zurück zum Zitat Wong P, et al. Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus. 2017;9(10):e1764.PubMedPubMedCentral Wong P, et al. Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus. 2017;9(10):e1764.PubMedPubMedCentral
97.
Zurück zum Zitat Callegaro D, et al. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. Br J Surg. 2015;102(9):1079–87.PubMedCrossRef Callegaro D, et al. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. Br J Surg. 2015;102(9):1079–87.PubMedCrossRef
98.
Zurück zum Zitat Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791–6.PubMedCrossRef Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791–6.PubMedCrossRef
99.
Zurück zum Zitat Anaya DA, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol. 2010;21(2):397–402.PubMedCrossRef Anaya DA, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol. 2010;21(2):397–402.PubMedCrossRef
100.
Zurück zum Zitat Raut CP, et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer. 2016;122(9):1417–24.PubMedCrossRef Raut CP, et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer. 2016;122(9):1417–24.PubMedCrossRef
101.
Zurück zum Zitat Tan MC, et al. Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg. 2016;263(3):593–600.PubMedCrossRef Tan MC, et al. Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg. 2016;263(3):593–600.PubMedCrossRef
102.
Zurück zum Zitat Dario Callegaro, C.P.R, Deanna Ng, Dirk C Strauss, Charles Honoré, Eberhard Stoeckle, MD Sylvie Bonvalot, Rick L Haas, Nikolaos Vassos, Lorenzo Conti, Rebecca Gladdy, Mark Fairweather, Winan van Houdt, Yvonne Schrage, Frits van Coevorden, Piotr Rutkowski, Rosalba Miceli, Alessandro Gronchi, Carol Swallow. Has the outcome of patients who undergo resection of primary retroperitoneal sarcoma changed over time? A time-trends study over the past 15 years. Ann Surg Oncol. 2020 (Submitted) Dario Callegaro, C.P.R, Deanna Ng, Dirk C Strauss, Charles Honoré, Eberhard Stoeckle, MD Sylvie Bonvalot, Rick L Haas, Nikolaos Vassos, Lorenzo Conti, Rebecca Gladdy, Mark Fairweather, Winan van Houdt, Yvonne Schrage, Frits van Coevorden, Piotr Rutkowski, Rosalba Miceli, Alessandro Gronchi, Carol Swallow. Has the outcome of patients who undergo resection of primary retroperitoneal sarcoma changed over time? A time-trends study over the past 15 years. Ann Surg Oncol. 2020 (Submitted)
103.
Zurück zum Zitat Khan AR, et al. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51(10):1147–56.PubMedCrossRef Khan AR, et al. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51(10):1147–56.PubMedCrossRef
Metadaten
Titel
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
verfasst von
Carol J. Swallow, MD, PhD
Dirk C. Strauss, MD
Sylvie Bonvalot, MD, PhD
Piotr Rutkowski, MD, PhD
Anant Desai, MD
Rebecca A. Gladdy, MD, PhD
Ricardo Gonzalez, MD
David E. Gyorki, MBBS, MD
Mark Fairweather, MD
Winan J. van Houdt, MD, PhD
Eberhard Stoeckle, MD
Jae Berm Park, MD, PhD
Markus Albertsmeier, PD, Dr.med.
Carolyn Nessim, MD, MSc
Kenneth Cardona, MD
Marco Fiore, MD
Andrew Hayes, MA, PhD
Dimitri Tzanis, MD, PhD
Jacek Skoczylas, MD
Samuel J. Ford, MB, ChB, PhD
Deanna Ng, MBBS
John E. Mullinax, MD
Hayden Snow, MBBS
Rick L. Haas, MD, PhD
Dario Callegaro, MD
Myles J. Smith, MB, BCh, BAO, PhD
Toufik Bouhadiba, MD
Silvia Stacchiotti, MD
Robin L. Jones, MBBS, MD(Res)
Thomas DeLaney, MD
Christina L. Roland, MD
Chandrajit P. Raut, MD MSc
Alessandro Gronchi, MD
on behalf of the Transatlantic Australasian RPS Working Group (TARPSWG)
Publikationsdatum
14.04.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-09654-z

Weitere Artikel der Ausgabe 12/2021

Annals of Surgical Oncology 12/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.